This is a preview of subscription content, log in via an institution to check access.
Notes
British pounds
skeletal-related events
Reference
Andronis L, et al. Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International : 3 Jun 2016. Available from: URL: http://doi.org/10.1111/bju.13549
Rights and permissions
About this article
Cite this article
Zoledronic acid and Sr89 cost effective in prostate cancer. PharmacoEcon Outcomes News 756, 36 (2016). https://doi.org/10.1007/s40274-016-3185-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3185-z